杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2025/07/11 | 1,489 | 1,502 | 1,483 | 1,500 | +14 | +0.9% | 77,600 |
2025/07/10 | 1,479 | 1,487 | 1,475 | 1,486 | +5 | +0.3% | 99,300 |
2025/07/09 | 1,470 | 1,492 | 1,470 | 1,481 | +13 | +0.9% | 51,800 |
2025/07/08 | 1,488 | 1,488 | 1,463 | 1,468 | -19 | -1.3% | 99,300 |
2025/07/07 | 1,490 | 1,496 | 1,482 | 1,487 | -3 | -0.2% | 125,400 |
2025/07/04 | 1,494 | 1,503 | 1,485 | 1,490 | +5 | +0.3% | 50,100 |
2025/07/03 | 1,484 | 1,491 | 1,475 | 1,485 | +4 | +0.3% | 67,100 |
2025/07/02 | 1,491 | 1,500 | 1,481 | 1,481 | -14 | -0.9% | 66,400 |
2025/07/01 | 1,517 | 1,521 | 1,494 | 1,495 | -21 | -1.4% | 80,800 |
2025/06/30 | 1,526 | 1,526 | 1,508 | 1,516 | -10 | -0.7% | 122,500 |
2025/06/27 | 1,500 | 1,526 | 1,498 | 1,526 | +18 | +1.2% | 301,000 |
2025/06/26 | 1,495 | 1,519 | 1,488 | 1,508 | +10 | +0.7% | 118,900 |
2025/06/25 | 1,531 | 1,531 | 1,472 | 1,498 | -19 | -1.3% | 235,900 |
2025/06/24 | 1,495 | 1,519 | 1,492 | 1,517 | +24 | +1.6% | 160,100 |
2025/06/23 | 1,458 | 1,496 | 1,456 | 1,493 | +28 | +1.9% | 136,700 |
2025/06/20 | 1,461 | 1,470 | 1,457 | 1,465 | -3 | -0.2% | 219,100 |
2025/06/19 | 1,482 | 1,487 | 1,462 | 1,468 | -14 | -0.9% | 53,600 |
2025/06/18 | 1,481 | 1,487 | 1,477 | 1,482 | +1 | +0.1% | 39,500 |
2025/06/17 | 1,484 | 1,491 | 1,475 | 1,481 | -3 | -0.2% | 66,300 |
2025/06/16 | 1,493 | 1,496 | 1,482 | 1,484 | +1 | +0.1% | 62,800 |
2025/06/13 | 1,498 | 1,498 | 1,476 | 1,483 | -19 | -1.3% | 137,900 |
2025/06/12 | 1,488 | 1,502 | 1,485 | 1,502 | +4 | +0.3% | 92,500 |
2025/06/11 | 1,493 | 1,512 | 1,493 | 1,498 | +13 | +0.9% | 98,200 |
2025/06/10 | 1,485 | 1,497 | 1,485 | 1,485 | -5 | -0.3% | 64,700 |
2025/06/09 | 1,502 | 1,503 | 1,482 | 1,490 | ±0 | ±0% | 56,500 |
2025/06/06 | 1,492 | 1,498 | 1,481 | 1,490 | -1 | -0.1% | 43,500 |
2025/06/05 | 1,490 | 1,496 | 1,483 | 1,491 | +1 | +0.1% | 57,000 |
2025/06/04 | 1,490 | 1,501 | 1,484 | 1,490 | ±0 | ±0% | 62,800 |
2025/06/03 | 1,498 | 1,498 | 1,480 | 1,490 | -8 | -0.5% | 70,500 |
2025/06/02 | 1,486 | 1,509 | 1,479 | 1,498 | -7 | -0.5% | 121,400 |
2025/05/30 | 1,466 | 1,505 | 1,459 | 1,505 | +35 | +2.4% | 318,100 |
2025/05/29 | 1,452 | 1,472 | 1,452 | 1,470 | +7 | +0.5% | 133,500 |
2025/05/28 | 1,450 | 1,465 | 1,446 | 1,463 | +8 | +0.5% | 122,400 |
2025/05/27 | 1,453 | 1,461 | 1,448 | 1,455 | -4 | -0.3% | 83,100 |
2025/05/26 | 1,458 | 1,464 | 1,447 | 1,459 | -1 | -0.1% | 81,200 |
2025/05/23 | 1,463 | 1,469 | 1,450 | 1,460 | -2 | -0.1% | 99,500 |
2025/05/22 | 1,456 | 1,468 | 1,446 | 1,462 | -7 | -0.5% | 89,300 |
2025/05/21 | 1,453 | 1,471 | 1,451 | 1,469 | +16 | +1.1% | 77,800 |
2025/05/20 | 1,477 | 1,481 | 1,453 | 1,453 | -13 | -0.9% | 130,600 |
2025/05/19 | 1,441 | 1,467 | 1,440 | 1,466 | +13 | +0.9% | 129,400 |
2025/05/16 | 1,445 | 1,455 | 1,433 | 1,453 | +12 | +0.8% | 79,900 |
2025/05/15 | 1,441 | 1,447 | 1,427 | 1,441 | -19 | -1.3% | 98,500 |
2025/05/14 | 1,460 | 1,471 | 1,437 | 1,460 | -16 | -1.1% | 120,300 |
2025/05/13 | 1,518 | 1,525 | 1,472 | 1,476 | +18 | +1.2% | 145,900 |
2025/05/12 | 1,488 | 1,495 | 1,458 | 1,458 | -30 | -2% | 125,000 |
2025/05/09 | 1,466 | 1,495 | 1,460 | 1,488 | +24 | +1.6% | 66,700 |
2025/05/08 | 1,478 | 1,481 | 1,454 | 1,464 | -6 | -0.4% | 73,400 |
2025/05/07 | 1,473 | 1,479 | 1,455 | 1,470 | -16 | -1.1% | 73,400 |
2025/05/02 | 1,471 | 1,492 | 1,471 | 1,486 | +11 | +0.7% | 78,800 |
2025/05/01 | 1,470 | 1,481 | 1,463 | 1,475 | +1 | +0.1% | 88,600 |
1~
50
件表示中 / 3740件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 150,000円 | -2.4% | -52.3% | 3.80% | 17.95倍 | 0.63倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 205,100円 | +3.1% | -6.5% | 2.34% | 9.52倍 | 1.01倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
持田薬 | 290,800円 | +5.1% | -7.0% | 2.75% | 19.09倍 | 0.79倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ネクセラファーマ | 88,200円 | +20.3% | - | 0.00% | 156.38倍 | 1.16倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 61,400円 | +14.3% | - | 3.26% | 24.94倍 | 1.59倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
市場注目の銘柄
チャート関連のコラム